Anyo Labs

ANYO Labs is focused on virtual screening and de novo small molecular drug generation in early-stage drug discovery projects. The unparalleled computational efficiency of our predictions opens up avenues never explored before allowing for data efficient and cost efficient hit identification. Supporting modules help aid hit-to-lead and lead optimization, while the PPI module can find correlations between hundreds of proteins simultaneously. Get in touch! We are open to discussing your potential projects, collaborations, or discuss any questions you might have

Drug discovery,ai,machine learning,target to hit,hit to lead,admet,biotech,virtual screening,pharmaceutical,small molecules,and omics

Anyo labs operates in the Biotechnology research industry.

Anyo labs's revenue is 11m - 100m

Anyo labs has 11 - 50 employees.